Accelerate timeline of your drug discovery project with our lead optimization programs
Developing an innovative therapy needs to build supporting evidences about the efficacy of the new molecule. For that, pharmaceutical companies must respect some key preclinical stages of the drug discovery process, including lead optimization.
Oncodesign Services, a leading CRO in early drug discovery, helps you to success on lead optimization step.
What is the lead optimization?
The key objective of Lead Optimization (LO) is to improve the pharmacological profile and DMPK properties of the Lead compound, such as efficacy, safety, pharmacokinetics and pharmacodynamics, to make it suitable for development into a drug candidate.
The lead optimization phase aims to identify a drug candidate, a molecule meeting the criteria defined in the Candidate Drug Target Profile (CDTP) to achieve the defined Target Product Profile (TPP). The selection of a drug candidate takes place at the end of the drug discovery phase, and the regulatory development phases then begin.
Lead optimization can take from 12 months up to 36 months, and the success rate is typically around 50%.
Oncodesign Services offers an integrated solution for Lead Optimization
Expert in translational sciences, Oncodesign Services has experienced scientific teams in drug metabolism and pharmacokinetics (DMPK/ADME) will help you to establish in-vitro, in-vivo and PK/PD correlations and predictions of human dose for promising candidates.
Our Lead Optimization capabilities include:
Multi-parameter optimization – AI
Multi-species PK & Allometric scaling
Early Scale-up and formulation
Early Safety assessment
Why choose Oncodesign Services for your lead optimization programs?
A multidisciplinary team with 25 years of experience in Drug Discover
All analytical capabilities in a unique company
A dedicated project leader as single point of contact
Expertise in various therapeutic areas (oncology, inflammation, infectious diseases…)